Topics

Immunogenic Cell Death (ICD)

Immunogenic Cell Death Cancer Immunotherapy

Immunogenic cell death (ICD) represents a distinct form of strategy in oncology, where dying cancer cells are converted into stimuli that drive long-lasting antitumor immunity (i.e. a source of in situ immunization). Unlike non-immunogenic apoptosis, ICD elicits robust immune activation through the release of damage-associated molecular patterns (DAMPs). By promoting immune recognition of tumor antigens, ICD bridges cell death and immune activation, transforming non-immunogenic "cold" tumors into highly infiltrated "hot" tumors [1] [2].

 

Mechanistically, ICD is initiated by endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) generation, which activate signaling cascades such as PERK/eIF2α/CHOP axis, resulting in type I interferon (IFN) responses and cytokine release (e.g., IL-1β, IFN-β, TNF-α). Key signs of ICD include: (1) calreticulin (CRT) exposure on the plasma membrane, (2) ATP secretion serving as chemoattractant, (3) HMGB1 release activating TLR4, and (4) uptake of dying or dead cells by dendritic cells (DCs) [3] [4] [5].

 

Established ICD induction strategies can be broadly divided into chemical agents (e.g. chemical protein phosphatase 1/GADD34 inhibitors) and physical approaches. There are two main types of ICD inducers – type I inducers (e.g. Oxa) and type II inducers, including IrIII NHC and AuI complexes. Metal complexes, in particular, have emerged as potent ICD inducers due to their chemical modularity and ability to target multiple stress pathways simultaneously. Nanoparticle-based ICD delivery systems are also gaining attention for their high efficiency and reduced systemic toxicity. In various preclinical models, ICD signaling has been associated with superior responses to cancer therapy, such as anthracyline-based chemotherapy, anticancer agents targeting epidermal growth factor (EGFR), multitarget tyrosine kinase inhibitors and radiation therapy [6] [7] [8].

 

Overall, harnessing and enhancing ICD holds great promise for transforming conventional cancer therapies into powerful, immune-driven treatment modalities.

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-16658B Z-VAD-FMK
Z-VAD-FMK is a pan-caspase inhibitor and also an ICE-like protease inhibitor, which inhibits apoptosis by preventing the processing of CPP32 to its active form. Z-VAD-FMK sensitivity varies primarily due to differential expression of receptor-interacting protein 1 (RIP1). Z-VAD-FMK limits the cryopreservation-induced apoptosis by reducing caspase-3 activity of in vitro produced bovine embryos. Z-VAD-FMK is immunosuppressive in vitro and inhibits T cell proliferation without blocking the processing of caspase-8 and caspase-3. Z-VAD-FMK leads to a decrease in intracellular glutathione (GSH) with a concomitant increase in reactive oxygen species (ROS) levels in activated T cells. Z-VAD-FMK is due to oxidative stress via the depletion of GSH. Z-VAD-FMK can be used for the study of acute pancreatitis.
Caspase   Apoptosis   RIP kinase   Glutathione Peroxidase   Reactive Oxygen Species (ROS)  
Cancer   Digestive System Disease   Pancreatitis  
850
HY-D0940 H2DCFDA
H2DCFDA (DCFH-DA) is a cell-permeable probe used to detect intracellular reactive oxygen species (ROS) (Ex/Em=488/525 nm).
Fluorescent Dye   Reactive Oxygen Species (ROS)  
838
HY-B0215 Acetylcysteine
Acetylcysteine (N-Acetylcysteine) is a mucolytic agent that can cross the blood-brain barrier, which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases. Acetylcysteine induces cell apoptosis. Acetylcysteine also has anti-influenza virus activities. In addition, Acetylcysteine ​​is the most stable form of cysteine ​​during drug delivery and can be used in disulfidptosis studies.
Reactive Oxygen Species (ROS)   Endogenous Metabolite   Apoptosis   Ferroptosis   Influenza Virus   Disulfidptosis  
Neurological, Eye or Ear Disease   Digestive System Disease   Breast Cancer   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection   Lung Fibrosis  
757
HY-10071 Y-27632
Y-27632 is a ROCK inhibitor with Ki values of 220 nM and 300 nM for ROCK1 and ROCK2, respectively. Y-27632 exerts anti-inflammatory and immunomodulatory effects in systemic lupus erythematosus models by inhibiting the ROCK/NF-κB pathway. Y-27632 enhances autophagy by inhibiting the AKT/mTOR pathway, thereby inducing apoptosis apoptosis in oral squamous cell carcinoma. Y-27632 induces the formation of tunneling nanotubes in ARPE-19 cells and significantly enhances mitochondrial transfer through these channels. Y-27632 promotes neurite outgrowth in PC12 cells by activating the Rac1/NOX1/ROS/AKT/PAK1 signaling cascade.
ROCK   Reactive Oxygen Species (ROS)   Akt   Ras   mTOR   Apoptosis   PAK   NADPH Oxidase   NF-κB   Autophagy  
Cancer   Digestive System Disease   Digestive System Inflammation   Lung Fibrosis  
602
HY-100218A RSL3
RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
p62   Glutathione Peroxidase   Ferroptosis   Reactive Oxygen Species (ROS)  
Ovarian Cancer  
573
HY-11109 Resatorvid
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
Toll-like Receptor (TLR)   TNF Receptor   Interleukin Related   Autophagy  
Prostate Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
536
HY-B0988 Deferoxamine mesylate
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.
Autophagy   HIF/HIF Prolyl-Hydroxylase   Reactive Oxygen Species (ROS)   Apoptosis   Akt  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
452
HY-D1055 MitoSOX Red
MitoSOX Red is a live cell fluorescent probe that specifically targets mitochondria and is cell membrane permeable. MitoSOX Red enters mitochondria and is oxidized by superoxide but not by other ROS or RNS generating systems. The oxidized MitoSOX Red then binds to nucleic acids in mitochondria/nucleus, producing strong red fluorescence. MitoSOX Red can be used as a fluorescent indicator to specifically detect superoxide. In addition, superoxide dismutase (SOD) can prevent the oxidation of MitoSOX Red.
Excitation/emission wavelength: 510/580 nm.
Fluorescent Dye   Reactive Oxygen Species (ROS)   Mitochondrial Metabolism  
Cancer  
328
HY-17371 Oxaliplatin
Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research.
DNA/RNA Synthesis   Apoptosis  
Prostate Cancer   Pancreatic Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer  
236
HY-18085 Quercetin
Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively.
PI3K   Autophagy   Mitophagy   Reactive Oxygen Species (ROS)   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Pain   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
230
HY-50895 Gefitinib
Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
EGFR   Autophagy   Apoptosis  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Lipid Metabolism   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Metastatic Breast Cancer   SARS-CoV-2 Infection  
222
HY-15772 Osimertinib
Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
EGFR  
Lung Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Glucose Metabolism   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
208
HY-100941 CCCP
CCCP is an oxidative phosphorylation (OXPHOS) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.
PINK1/Parkin   Oxidative Phosphorylation   STING   IFNAR   Mitochondrial Metabolism   Bacterial   Apoptosis  
Cancer   Digestive System Disease   Bacterial Infection   Digestive System Inflammation   Parkinson's Disease   Rheumatoid Arthritis  
192
HY-B2176 ATP
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.

Source: widespread

Endogenous Metabolite   NOD-like Receptor (NLR)   Interleukin Related   Bacterial  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
178
HY-B0240 Disulfiram
Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu2+ increases intracellular ROS levels and induces cuproptosis.
Aldehyde Dehydrogenase (ALDH)   Interleukin Related   Pyroptosis   Apoptosis   Cuproptosis  
Metabolic or Endocrine Disease   Breast Cancer   Prostate Cancer   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Autoimmune Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
161
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-50896 Erlotinib
Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.
EGFR   OAT   ERK   GSK-3   β-catenin  
Gastric Cancer   Pancreatic Cancer   Renal Disease   Non-Small Cell Lung Cancer   Lung Adenocarcinoma  
147
HY-18072 GSK2606414
GSK2606414 is a cell-permeable and orally available protein kinase R-like endoplasmic reticulum (ER) kinase (PERK) inhibitor with an IC50 of 0.4 nM.
PERK   Autophagy   Apoptosis  
Cancer   Digestive System Disease   Digestive System Inflammation  
135
HY-10261 Afatinib
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.
EGFR   Autophagy   Apoptosis   c-Met/HGFR   Akt   p38 MAPK  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Hepatitis C Virus Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
113
HY-13756 Tacrolimus
Tacrolimus (FK506), a molecular glue, a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.

Source: fungus Streptomyces tsukubaensis.

Phosphatase   FKBP   Molecular Glues   Bacterial   Autophagy   Antibiotic  
Inflammation or Immune System Disease  
107
HY-50898 Lapatinib
Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
EGFR   Autophagy   Ferroptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   HER-2 Positive Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
100
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

100
HY-14596 Genistein
Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
EGFR   Autophagy   Apoptosis   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Lung Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
94
HY-B0166 L-Ascorbic acid
L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells.
Endogenous Metabolite   Apoptosis   Reactive Oxygen Species (ROS)   Calcium Channel  
Neurological, Eye or Ear Disease   Pancreatic Cancer   Digestive System Inflammation   Glucose Metabolism   SARS-CoV-2 Infection   Hypertension  
91
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-14519 Methotrexate
Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
Antifolate   Dihydrofolate reductase (DHFR)   NO Synthase   COX   Interleukin Related  
Breast Cancer   Arthritis   Systemic Lupus Erythematosus   Psoriasis   Lung Fibrosis  
87
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L083 Anti-Cancer Metabolism Compound Library
Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth. MCE provides a unique collection of 3,806 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.

Signaling Pathway Targeting Libraries

84
HY-L188 Anti-Brain Cancer Compound Library
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets. MCE designs a unique collection of 2,134 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
84
HY-L074 Anti-Breast Cancer Compound Library
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 3,404 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Disease Focused Libraries

83
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L103 Anti-Colorectal Cancer Compound Library
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,653 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L135 Cancer Stem Cells Compound Library
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on. Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment. MCE supplies a unique collection of 3,540 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

Compound Characteristic Classified Libraries

83
HY-L156 Autoimmune Disease Compound Library
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A). MCE designs a unique collection of 1,040 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Disease Focused Libraries

83
HY-L171 Anti-Hematopathy Compound Library
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 4,388 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Disease Focused Libraries

83
HY-L173 Anti-Ovarian Cancer Compound Library
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer. MCE designs a unique collection of 2,967 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Disease Focused Libraries

83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L219 Antimicrobial Peptides Library
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development. MCE offers 58 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
83
HY-L224 Diarrhea-Related Traditional Chinese Medicine Active Compound Library
Diarrhea is a disease symptom, and the pathophysiologic basis of diarrhea is a disturbance in intestinal water and electrolyte balance, which may be due to increased secretion of osmotically active electrolytes (secretory diarrhea) or increased intake of osmotically active substances (osmotic diarrhea). Food poisoning, pathogenic bacterial infections, and intestinal-related diseases can all contribute to the development of diarrhea. Traditional Chinese Medicine (TCM) considers diarrhea to be a symptom of an imbalance in the body's systems, particularly related to the functions of the spleen and stomach. Spleen qi deficiency, dampness-heat, liver and spleen disharmony are closely related to diarrhea. Many types of Chinese herbs regulate the function of diarrhea, such as: Dysosmae Verspiellis Rhixoma Et Radix, Ginkgo Semen, Forsythiae Fructus, and Campsis Flos. MCE can provide 2,478 active monomers that can be obtained from TCM herbs with diarrhea-regulating functions, which can be applied to drug development and disease mechanism research.

Traditional Chinese Medicine Libraries

83
HY-L237 Pattern Recognition Receptors Library
Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions. MCE has cataloged 338 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.
83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-10964 Vadimezan
Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
STING   IFNAR   Influenza Virus  
Lung Cancer   Prostate Cancer   Viral Infection   Autoimmune Disease   SARS-CoV-2 Infection  
80
HY-N0822 Shikonin
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
Exosomes   Chloride Channel   Pyruvate Kinase   NF-κB   TNF Receptor   HIV   AIM2  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
74
HY-107202 Polyinosinic-polycytidylic acid
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
RIG-I-like receptor (RLR)   Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Digestive System Disease   Prostate Cancer   Pain   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
73
HY-P9907 Trastuzumab
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)

Species: Human

Radionuclide-Drug Conjugates (RDCs)   EGFR   ADC Antibodies  
Non-Small Cell Lung Cancer   Luminal Breast Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
71
HY-13820 GSK2656157
GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) with an IC50 of 0.9 nM.
PERK   Autophagy   Apoptosis  
Cancer   Digestive System Disease   Digestive System Inflammation  
67
HY-112654 GCN2iB
GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC50 of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy.
Eukaryotic Initiation Factor (eIF)   Glutathione Peroxidase  
Glucose Metabolism   Acute Myeloid Leukemia   Acute Lymphoblastic Leukemia   Cardiomyopathy  
65
HY-A0003 Lenalidomide
Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8+ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury.
Molecular Glues   Ligands for E3 Ligase   IKZF Family   Casein Kinase   Apoptosis   Pyroptosis   MDM-2/p53   TNF Receptor  
Inflammation or Immune System Disease   Renal Disease   Chronic Lymphocytic Leukemia   Diffuse Large B-cell Lymphoma   Multiple Myeloma   Myelodysplastic Syndrome   Liver Failure  
63
HY-108841 Raleukin
Raleukin (Kineret) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin significantly reduces neutrophil accumulation in blood vessels and brain infarct volume as well as improves motor coordination performance in ischemic stroke mice model. Anakinra can be used to study chronic inflammatory disorders like rheumatoid arthritis and cardiovascular recurrence post-myocardial infarction.

Species: Human

Interleukin Related  
Metastatic Breast Cancer   SARS-CoV-2 Infection   Rheumatoid Arthritis  
57
HY-P9905 Cetuximab
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

Species: Human

Radionuclide-Drug Conjugates (RDCs)   EGFR  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
57
HY-13251 Silvestrol
Silvestrol is a eukaryotic translation initiation factor 4A (eIF4A) inhibitor isolated from Agave americana Linn.. Silvestrol induces autophagy and caspase-mediated apoptosis.
Eukaryotic Initiation Factor (eIF)   Apoptosis   Autophagy  
54
HY-10159A Nilotinib monohydrochloride monohydrate
Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against BCR-ABL, and is active against many BCR-ABL mutants.
Bcr-Abl   Autophagy  
Leukemia/Lymphoma/Myeloma   Alzheimer's Disease   Parkinson's Disease  
53
HY-B0764 Bucladesine sodium
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation.
PKA   Reactive Oxygen Species (ROS)   Apoptosis  
Cancer   Inflammation or Immune System Disease   Alzheimer's Disease  
52
HY-12495 ISRIB (trans-isomer)
ISRIB (trans-isomer) is a potent inhibitor of PERK with an IC50 of 5 nM. ISRIB potently reverses the effects of eIF2α phosphorylation (IC50=5 nM).
PERK   Autophagy   Apoptosis  
Neurological, Eye or Ear Disease   Digestive System Disease   Digestive System Inflammation  
50
HY-B1081A Oxidopamine hydrobromide
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.
Dopamine Receptor   Autophagy   Mitophagy   COX   PGE synthase   Interleukin Related   p38 MAPK   Apoptosis   Caspase  
Breast Cancer   Parkinson's Disease  
50
HY-15486 Salubrinal
Salubrinal is a cell-permeable and selective inhibitor of eIF2α dephosphorylation. Salubrinal acts as a dual-specificity phosphatase 2 (Dusp2) inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis. Salubrinal has antiviral activity against HSV-1 and inhibits dephosphorylation of eIF2α mediated by the HSV-1 protein ICP34.5.
Phosphatase   HSV   Autophagy   Apoptosis  
Cancer   Digestive System Disease   Viral Infection   Digestive System Inflammation  
44
HY-100564A 2',3'-cGAMP sodium
2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP sodium binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP sodium is produced in mammalian cells in response to DNA in the cytoplasm.
Endogenous Metabolite   STING   IFNAR  
Metabolic or Endocrine Disease  
44
HY-100564 2',3'-cGAMP
2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm.
Endogenous Metabolite   STING   IFNAR  
Metabolic or Endocrine Disease  
44
HY-119240 CCT020312
CCT020312 is a selective EIF2AK3/PERK activator. CCT020312 elicits EIF2A phosphorylation in cells.
PERK   Autophagy  
Cancer   Neurological, Eye or Ear Disease  
43
HY-12495A ISRIB
ISRIB is a brain-penetrant inhibitor of integrated stress response (ISR). Persistent activation of the ISR has been linked to the development of several neurological disorders as ISR represses translation through inhibiting eIF2B. ISRIB inhibits the ISR by promoting the nucleotide exchange activity of eIF2B and recovering the translation, and thus can be used for neurological disorders research.
Biochemical Assay Reagents   Eukaryotic Initiation Factor (eIF)  
Neurological, Eye or Ear Disease  
37
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-117287 Deucravacitinib
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
JAK   STAT   Interleukin Related   IFNAR  
Systemic Lupus Erythematosus   Psoriasis   Inflammatory Bowel Disease  
36
HY-126304 β-Glycerophosphate disodium salt hydrate
β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells.
Phosphatase   Endogenous Metabolite   ERK  
Metabolic or Endocrine Disease   Pancreatic Cancer   Depression   Pain   Lung Fibrosis  
35
HY-N0182 Fisetin
Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
Sirtuin   PPAR   TNF Receptor  
Digestive System Disease   Prostate Cancer   Viral Infection   Depression   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
35
HY-D0886 β-Glycerophosphate disodium salt pentahydrate
β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells.
Phosphatase   Endogenous Metabolite   ERK  
Cancer   Metabolic or Endocrine Disease  
35
HY-19356 Rocaglamide
Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC50 of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.
NF-κB   HSP   Eukaryotic Initiation Factor (eIF)  
Inflammation or Immune System Disease  
32
HY-P9970 Infliximab
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
The component ratio of this product is Active ingredient : Excipients = 9 : 47.

Species: Human

TNF Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Lung Cancer   Breast Cancer  
30
HY-13750 Ebselen
Ebselen (SPI-1005), a glutathione peroxidase mimetic, is a potent voltage-dependent calcium channel (VDCC) blocker. Ebselen potently inhibits Mpro (IC50=0.67 μM) and COVID-19 virus (EC50=4.67 μM).Ebselen is an inhibitor of HIV-1 capsid CTD dimerization. Ebselen, an organoselenium compound, can permeate the blood-brain barrier and has anti-inflammatory, antioxidant and anticancer activity.
Calcium Channel   Virus Protease   HIV   Phosphatase  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Viral Infection   SARS-CoV-2 Infection   Hypertension  
28
HY-100877 GCN2-IN-1
GCN2-IN-1 is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with an IC50 of <0.3 μM in the enzyme assay and an IC50 of 0.3-3 μM in the cell assay.
Eukaryotic Initiation Factor (eIF)  
Cancer  
27
HY-10158 Bosutinib
Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively.
Src   Bcr-Abl   Autophagy  
Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Ovarian Cancer   Pain   Metastatic Breast Cancer   Chronic Myelogenous Leukemia   Non-Hodgkin Lymphoma   Multiple Myeloma   Glioblastoma   Alzheimer's Disease   Parkinson's Disease   Lung Fibrosis  
25
HY-N6785 Okadaic acid
Okadaic acid, a marine toxin, is an inhibitor of protein phosphatases (PP). Okadaic acid has a significantly higher affinity for PP2A (IC50=0.1-0.3 nM), and inhibits PP1 (IC50=15-50 nM), PP3 (IC50=3.7-4 nM), PP4 (IC50=0.1 nM), PP5 (IC50=3.5 nM), but does not inhibit PP2C. Okadaic acid increases of phosphorylation of a number of proteins by inhibiting PP, and acts a tumor promoter. Okadaic acid induces tau phosphorylation.

Source: bivalve mollusks

Phosphatase   Apoptosis  
Cancer   Neurological, Eye or Ear Disease  
24
HY-B0879A Suramin sodium salt
Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM). Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM). Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor. Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.
Phosphatase   Sirtuin   Reverse Transcriptase   Topoisomerase   SARS-CoV   Parasite   Apoptosis  
Digestive System Disease   Lung Cancer   Prostate Cancer   Viral Infection   Parasitic Infection   Digestive System Inflammation   Cardiovascular Disease  
23
HY-18983 Calyculin A
Calyculin A ((-)-Calyculin A) is a potent and cell-permeable protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) inhibitor with IC50s of 2 nM and 0.5-1 nM, respectively.
Phosphatase  
Cancer  
20
HY-P9908 Adalimumab
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).

Species: Human

TNF Receptor   Bacterial  
Cancer   Autoimmune Disease  
20
HY-19831 4EGI-1
4EGI-1 is an inhibitor of eIF4E/eIF4G interaction, with a Kd of 25 μM against eIF4E binding.
Eukaryotic Initiation Factor (eIF)   Autophagy   Apoptosis  
Digestive System Disease   Breast Cancer   Digestive System Inflammation  
18
HY-134581 Enpatoran
Enpatoran (M5049) is an orally active and selective TLR7/8 antagonist. Enpatoran inhibits the activation of the downstream type I interferon pathway. Enpatoran is used in studies of cutaneous lupus erythematosus, systemic lupus erythematosus with cutaneous manifestations, and psoriasis.
Toll-like Receptor (TLR)   IFNAR  
Systemic Lupus Erythematosus   Psoriasis  
18
HY-148439 Daraxonrasib
Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors.
Ras   PERK  
Respiratory Disease   Colorectal Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Non-Small Cell Lung Cancer  
18
HY-108847 Etanercept
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
TNF Receptor   Bacterial  
Cancer   Rheumatoid Arthritis  
16
HY-D0852 Sodium orthovanadate
Sodium orthovanadate is an inhibitor of protein tyrosine phosphatases, alkaline phosphatases and a number of ATPases, most likely acting as a phosphate analogue.
Phosphatase  
Cancer  
14
HY-12661A AMG PERK 44
AMG PERK 44 is an orally active and highly selective PERK inhibitor with an IC50 of 6 nM. AMG PERK 44 has 1000-fold and 160-fold selectivity over GCN2 (IC50=7300 nM) and B-Raf (IC50 >1000 nM), respectively. AMG PERK 44 induces autophagy.
PERK   Autophagy  
Cancer  
13
HY-107837 L-Ascorbic acid 2-phosphate trisodium
L-Ascorbic acid 2-phosphate trisodium (2-Phospho-L-ascorbic acid trisodium) is a long-acting vitamin C derivative that can stimulate collagen formation and expression. L-Ascorbic acid 2-phosphate trisodium (2-Phospho-L-ascorbic acid trisodium) can be used as a culture medium supplement for the osteogenic differentiation of human adipose stem cells (hASCs). L-Ascorbic acid 2-phosphate trisodium (2-Phospho-L-ascorbic acid trisodium) increases alkaline phosphatase (ALP) activity and expression of runx2A in hASCs during the osteogenic differentiation.
Phosphatase   Reactive Oxygen Species (ROS)   Endogenous Metabolite  
Metabolic or Endocrine Disease  
12
HY-103701 L-Ascorbic acid 2-phosphate
L-ascorbic acid 2-phosphate (2-Phospho-L-ascorbic acid) is a long-acting vitamin C derivative that can stimulate collagen formation and expression. L-ascorbic acid 2-phosphate (2-Phospho-L-ascorbic acid) can be used as a culture medium supplement for the osteogenic differentiation of human adipose stem cells (hASCs). L-ascorbic acid 2-phosphate increases alkaline phosphatase (ALP) activity and expression of runx2A in hASCs during the osteogenic differentiation.
Phosphatase   Reactive Oxygen Species (ROS)   Endogenous Metabolite  
Metabolic or Endocrine Disease  
12
HY-138298 Trastuzumab deruxtecan (solution)
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
Antibody-Drug Conjugates (ADCs)   EGFR  
Breast Cancer   Gastric Cancer  
12
HY-138298A Trastuzumab deruxtecan
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
Antibody-Drug Conjugates (ADCs)   EGFR  
Breast Cancer  
12
HY-112163 Zotatifin
Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM) and interferes with the assembly of the eIF4F initiation complex. Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC90=37 nM). Zotatifin induces cell apoptosis.
Eukaryotic Initiation Factor (eIF)   SARS-CoV   Apoptosis  
10
HY-107780A Cyclic-di-GMP sodium
Cyclic-di-GMP sodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP sodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP sodium can be used in cancer research.

Source: bacterial species

STING   Endogenous Metabolite  
9
HY-107780 Cyclic-di-GMP
Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research.

Source: bacterial species

STING   Endogenous Metabolite  
9
HY-107780B Cyclic-di-GMP diammonium
Cyclic-di-GMP diammonium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research.
STING   Endogenous Metabolite  
Cancer   Bacterial Infection  
9
HY-110382 Cyclic-di-GMP disodium
Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research.
STING   Endogenous Metabolite  
9
HY-P9926 Dupilumab
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Breast Cancer   Non-Small Cell Lung Cancer   Staphylococcus Aureus Infection  
9
HY-13822 SKI II
SKI-II is an orally active dual-target inhibitor of SphK1/2 and DES1, with Ki values of 16 µM and 0.3 µM against SphK1 and DES1, respectively. SKI-II activates the PERK-Nrf2 antioxidant pathway by stabilizing Nrf2, and synergizes with Temozolomide (HY-17364) to induce oxidative/endoplasmic reticulum stress and cancer cell death under hypoxic conditions. In vivo, SKI-II inhibits SphK activity, promotes ceramide accumulation and apoptosis, and synergizes with Cisplatin (HY-17394) to reverse drug resistance via the ras/MAPK pathway. SKI-II reduces measles virus replication by inhibiting mTORC1 activity. SKI-II binds to VCP to induce M1 polarization, enhances host tolerance to Staphylococcus aureus infection, and exerts radioprotective effects through Nrf2 activation and accelerated DNA repair. SKI-II can be used in research related to glioblastoma, acute myeloid leukemia, gastric cancer, measles virus infection, Staphylococcus aureus infection, and acute radiation syndrome.
SphK   Dihydroceramide Desaturase 1 (DES1)   Apoptosis   Reactive Oxygen Species (ROS)   mTOR   PERK   Keap1-Nrf2  
Gastric Cancer   Acute Myeloid Leukemia   Glioblastoma   Measles Virus Infection   Staphylococcus Aureus Infection  
8
HY-107632 GYY4137
GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity.
Apoptosis   STAT   NF-κB   NO Synthase   COX   TNF Receptor   Interleukin Related  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
8
HY-147124 RIG012
RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.
IFNAR  
Cancer   Infection  
6
HY-W250978 Ovalbumins
Ovalbumins are the major proteins in egg white. Ovalbumins act as an allergen and inducer, and can be applied to mouse models of allergic diseases. Ovalbumins can induce allergic rhinitis in mice via sensitization and nasal challenge. Ovalbumins can be used to establish asthma models.
Ovalbumin, low endotoxin (HY-W250978A) is recommended for model establishment.
Interleukin Related   IFNAR  
Allergic Asthma   Allergic Rhinitis  
6
HY-P99168 Anifrolumab
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.

Species: Human

IFNAR  
Systemic Lupus Erythematosus   Rheumatoid Arthritis  
5
HY-N2435 [8]-Shogaol
[8]-Shogaol, a kind of stimulating compound in ginger, has antiplatelet (IC50=5 μM), anti-cancer and anti-inflammatory activity. [8]-Shogaol inhibited COX-2 (IC50=17.5 μM), which led to the decline of human leukemia cells. 8-Shogaol Selective direction TAK1 sum TAK1-TAB1 (IC50=5 μM), suppress IKK, Akt sum MAPK signal pathway, and reverse synovitis synovial sum Air dampness (RA).
COX   Apoptosis  
Colorectal Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Depression   Digestive System Inflammation   Rheumatoid Arthritis  
4
HY-125021 2BAct
2BAct is a highly selective, orally active, and CNS-penetrant eIF2B (eukaryotic initiation factor 2B) activator with an EC50 of 33 nM. 2BAct prevents neurological defects caused by a chronic integrated stress response. 2BAct displays improved solubility and pharmacokinetics relative to eIF2B activator ISRIB trans-isomer (HY-12495).
Eukaryotic Initiation Factor (eIF)  
Neurological, Eye or Ear Disease  
4
HY-P7696 CA125 Protein, Human (HEK293, His)
CA125 is a giant mucin-like glycoprotein expressed by epithelial ovarian neoplasms and cells, which is an antigenic tumor marker. CA125 provides a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. CA125 binds to mesothelin (MSLN) mediates heterotypic cell adhesion, contributing to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium. CA125 is widely used for monitoring with ovarian epithelial cancer. CA125 Protein, Human (HEK293, His) is a recombinant human cancer antigen 125 (CA125) with a His label and is expressed in HEK293 cells.

Species: Human; Source: HEK293

CAR-T Related Proteins CA-125

4
HY-101925 CM-272
CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities. CM-272 inhibits G9a, DNMT1, DNMT3A, DNMT3B and GLP with IC50s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis, inducing IFN-stimulated genes and immunogenic cell death.
Histone Methyltransferase   DNA Methyltransferase   Apoptosis  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation   Rheumatoid Arthritis  
3
HY-P99151 Brentuximab
Brentuximab (CAC-10) is a chimeric antibody targeting CD30. Brentuximab is conjugated with Monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107A). Brentuximab can be used for the research of cancer, such as lymphoma.

Species: Human

ADC Antibodies   TNF Receptor  
Leukemia/Lymphoma/Myeloma  
3
HY-164992 Trastuzumab vedotin
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma.
Antibody-Drug Conjugates (ADCs)   EGFR   Microtubule/Tubulin  
Gastric Cancer   Metastatic Breast Cancer   Urothelial Cancer  
3
HY-13673 Goserelin
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
GnRH Receptor   Apoptosis  
Metabolic or Endocrine Disease   Luminal Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
2
HY-10421 Tyrosine kinase inhibitor
Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor.
c-Met/HGFR  
Lung Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer  
2
HY-13673A Goserelin acetate
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
GnRH Receptor   Apoptosis  
Metabolic or Endocrine Disease   Luminal Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
2
HY-119109 Laminaran
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.

Source: Eisenia Bicyclis

Environmental Pollutants   C-type Lectin-like Receptors (CTLRs)   Endogenous Metabolite  
Colorectal Cancer  
2
HY-P9981 Tafasitamab
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.

Species: Human

Apoptosis  
Cancer   Inflammation or Immune System Disease  
2
HY-N2435R [8]-Shogaol (Standard)
-Shogaol (Standard) is the analytical standard of -Shogaol. This product is intended for research and analytical applications. -Shogaol, a kind of stimulating compound in ginger, has antiplatelet (IC50=5 μM), anti-cancer and anti-inflammatory activity. -Shogaol inhibited COX-2 (IC50=17.5 μM), which led to the decline of human leukemia cells. 8-Shogaol Selective direction TAK1 sum TAK1-TAB1 (IC50=5 μM), suppress IKK, Akt sum MAPK signal pathway, and reverse synovitis synovial sum Air dampness (RA).
Reference Standards   COX   Apoptosis  
Cancer  
1
HY-150611 EGFR-IN-70
EGFR-IN-70 (compound 18j) is a potent EGFR inhibitor with IC50 values of 23.6 and 307.5 nM for EGFRLR/TM/CS and EGFRWT, respectively. EGFR-IN-70 has anti-proliferative activity and suppresses phosphorylation of the EGFR. EGFR-IN-70 can be used for cancer research.
EGFR  
Lung Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Hepatitis C Virus Infection   Obesity  
1
HY-N5084 Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer.
TRP Channel   HDAC   p38 MAPK   JNK   ERK   NF-κB   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Bladder Cancer   Pain  
1
HY-135220 PERK-IN-2
PERK-IN-2 is a potent PERK inhibitor with an IC50 of 0.2 nM.
PERK  
Cancer  
1
HY-N0819 Raddeanin A
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
Apoptosis   PI3K   Akt   ERK   mTOR   Wnt   β-catenin   Wee1   JNK   VEGFR   CDK  
Colorectal Cancer   Leukemia/Lymphoma/Myeloma   Cancer Immunology   Digestive System Inflammation   Non-Small Cell Lung Cancer   Immunotherapy for Melanoma   Alzheimer's Disease  
1
HY-W050044 L-Azetidine-2-carboxylic acid
L-Azetidine-2-carboxylic acid is a proline analog. L-Azetidine-2-carboxylic acid upregulates the lipid autophagy marker LC3-II via activation of the PERK pathway. L-Azetidine-2-carboxylic acid increases pro-apoptotic BAX protein. L-Azetidine-2-carboxylic acid induces ATF6 cleavage and upregulates phosphorylated eIF2α levels. L-Azetidine-2-carboxylic acid induces ER stress, inducing protein misfolding and aggregation. L-Azetidine-2-carboxylic acid shows teratogenic, pro-inflammatory and pro-apoptotic effects.
Endogenous Metabolite   PERK   Atg8/LC3   Autophagy   Bcl-2 Family   Apoptosis   Eukaryotic Initiation Factor (eIF)   ATF6  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease  
1
HY-108666 ATPγS tetralithium salt
ATPγS (tetralithium salt) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATPγS (tetralithium salt) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATPγS (tetralithium salt) is active in ATP hydrolysis.
Eukaryotic Initiation Factor (eIF)   P2Y Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-P990007 Tulisokibart
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis.

Species: Human

TNF Receptor  
Digestive System Inflammation   Crohn's Disease   Ulcerative Colitis  
1
HY-K6105 Human Gastric Cancer Organoid Kit

MCE Human Gastric Cancer Organoid Kit contains Gastric Cancer Organoid Basal Medium A, Gastric Cancer Organoid Supplement B (50×), Gastric Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human gastric cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

1
HY-151503 MPM-1
MPM-1, a marine Eusynstyelamides mimic, is a potent anticancer agent. MPM-1 can rapidly kill cancer cells in vitro by inducing a necrosis-like death. MPM-1 has the ability to induce immunogenic cell death. MPM-1 causes perturbation of autophagy and lysosomal swelling in cancer cells.
Autophagy  
/
HY-160261S EP300/CBP-IN-2
EP300/CBP-IN-2 is a potent EP300/CBP inhibitor that has good activity in vivo. EP300/CBP-IN-2 can be used for the research of cancer.
Histone Acetyltransferase   Epigenetic Reader Domain  
Cancer  
/
HY-N17453 (+)-Mornaphthoate E
(+)-Mornaphthoate E is a growth inhibitor that suppresses cancer cell proliferation. It can be used in research on cancers such as lung cancer and breast cancer.
Others  
Breast Cancer   Non-Small Cell Lung Cancer  
/
HY-N17825 Terrestroside A
Terrestroside A is an anticancer agent. Terrestroside A inhibits the growth of various cancer cells in vitro. Terrestroside A can be used for the research of lung cancer, central nervous system cancer and breast cancer.
Others  
Lung Cancer   Breast Cancer  
/
HY-163587 PRMT5-IN-39-d3
PRMT5-IN-39-d3 is the deuterated form of PRMT5-IN-39. PRMT5-IN-39-d3 is an orally active PRMT5 inhibitor and can be used for study of cancer.
Histone Methyltransferase  
Cancer  
/
HY-P11624 PP-60
PP-60 is an apoptosis inducer. PP-60 inhibits the proliferation of cancer cells and induces cancer cell apoptosis. PP-60 exerts anti-tumor effects in nude mouse liver tumor models. PP-60 is applicable to research related to cancers such as liver cancer, lung cancer, and prostate cancer.
Apoptosis  
Lung Cancer   Prostate Cancer   Liver Cancer  
/
HY-N19739 Efrapeptin F
Efrapeptin F is a mitochondrial complex V inhibitor and cytotoxic agent with in vivo antitumor activity. Efrapeptin F induces cell death in glucose-limiting conditions, with preferential cytotoxicity to nutrient-deprived cancer cells under hypoxic conditions. Efrapeptin F can be used for the research of pancreatic cancer, prostate cancer, breast cancer, central nervous system cancer, colon cancer, lung cancer, melanoma, ovarian cancer, kidney cancer, stomach cancer.

Source: Tolypocladium fungi

Mitochondrial Metabolism  
Cancer  
/
HY-P991292 AB-3A4
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

ADC Antibodies  
Cancer  
/
HY-D3158 LGP-CL
LGP-CL is a chemiluminescent probe. LGP-CL can be used to evaluate elevated protease levels in both in vitro and in vivo systems, and to distinguish hepatocellular carcinoma cells from normal cells and other cancer cell lines. LGP-CL is applicable to liver cancer-related research.
Fluorescent Dye  
Liver Cancer  
/
HY-N18236 3β-Acetoxyl-atractylenolide I
3β-Acetoxyl-atractylenolide I is a LSD1 inhibitor with an IC50 of 57 μM. 3β-Acetoxyl-atractylenolide I blocks tumor growth, metastasis and invasion. 3β-Acetoxyl-atractylenolide I is used in the research of various cancers including prostate cancer, breast cancer, neuroblastoma, gastric cancer, colon cancer, bladder cancer, esophageal cancer, acute myeloid leukemia and retinoblastoma.
Histone Demethylase  
Breast Cancer   Prostate Cancer   Gastric Cancer   Bladder Cancer   Acute Myeloid Leukemia   Esophageal Cancer  
/
HY-164107 Auristatin S
Auristatin S is a potent Auristatin payload. Auristatin S binds to the vinca-binding site on tubulin, thereby inhibiting microtubule assembly and inducing cell cycle arrest and apoptosis. Auristatin S acts as a cytotoxic component of antibody-drug conjugates (ADCs) and exerts target-specific cytotoxicity against cancer cells. Auristatin S can be used in the research of lymphoma, anaplastic large cell lymphoma and Hodgkin lymphoma.
ADC Payloads   Microtubule/Tubulin   Apoptosis  
Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
/
HY-P11658 Anticancer peptoid 1
Anticancer peptoid 1 (Peptoid 1) is a peptoid with antitumor activity. Anticancer peptoid 1 exerts cytotoxicity primarily via plasma membrane damage. Anticancer peptoid 1 exerts cytotoxicity against a broad range of cancer cell lines, including those with multidrug resistance. Anticancer peptoid 1 inhibits tumor growth in a human breast cancer xenotransplantation mouse model without noticeable acute adverse effects. Anticancer peptoid 1 can be used for the research of cancer, such as breast cancer, and prostate cancer.
Others  
Breast Cancer   Prostate Cancer  
/
HY-182259 Montanastatin
Montanastatin is an antitumor agent that can be isolated from the terrestrial actinomycete Streptomyces anulatus. Montanastatin inhibits the growth of various cancer cells. Montanastatin can be used in research related to lymphocytic leukemia, ovarian cancer, brain cancer, renal cancer, lung cancer, colon cancer and melanoma.
Others  
Lung Cancer   Colorectal Cancer   Leukemia/Lymphoma/Myeloma   Melanoma   Ovarian Cancer   Renal Cancer  
/
HY-126412 Neochamaejasmine A
Neochamaejasmine A is a biflavonoid that can be isolated from the roots of Stellera chamaejasme L.. Neochamaejasmine A inhibits proliferation, induces cell cycle arrest and apoptosis in tumor cells. Neochamaejasmine A can be used in the research of cancers such as prostate cancer, hepatoma cancer.
Apoptosis  
/
HY-N20331 Exocarpium citri rubrum extract
Exocarpium citri rubrum extract (Citri exocarpium rubrum extract) is an extract of citrus rubrum (Exocarpium Citri Rubrum) that has the effects of removing dampness and resolving phlegm.
Others  
Gastric Disease  
/
HY-P11601 MAF-10L
MAF-10L is a membrane-disrupting agent, a cationic amphipathic Mastoparan AF derivative with enhanced α-helicity. MAF-10L preferentially interacts with DOPS lipids in cancer cell membranes, disrupting cancer cell membranes to trigger membrane leakage. MAF-10L can be used for the research of cancer.
Biochemical Assay Reagents  
Cancer  
/
HY-W263279 (E)-Guanabenz
(E)-Guanabenz ((E)-Wy-8678) is an orally active central α2-adrenoceptor agonist. (E)-Guanabenz has antihypertensive activity, acts via stimulating central α2-adrenoceptors, and reducing net sympathetic outflow into the periphery. (E)-Guanabenz also directly binds to and inhibits GADD34, and has neuroprotective activity. (E)-Guanabenz can be used for researching hypertension and Parkinson disease.
Adrenergic Receptor  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-D3182 AldRed 588-A
AldeRed 588-A is a fluorescent labeling reagent and a substrate for aldehyde dehydrogenase (ALDH). AldeRed 588-A is metabolized by functionally active ALDH enzymes, thereby specifically labeling viable ALDHbright cell populations with red-shifted fluorescence. AldeRed 588-A supports one-step isolation and sorting of ALDH-expressing cells (including normal stem cells and cancer stem cells), and can be used in combination with green fluorophores for multicolor experimental applications. AldeRed 588-A is widely applicable to research related to various cancers such as bladder cancer, breast cancer, and head and neck cancer.
Fluorescent Dye   Aldehyde Dehydrogenase (ALDH)  
Cancer  
/
HY-P11205 Cys-PKHB1
Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
CD47   Reactive Oxygen Species (ROS)   Thrombopoietin Receptor  
Inflammation or Immune System Disease  
/
HY-P992021 WM-A1-3389
WM-A1-3389 is an anti-human IGSF1monoclonal antibody and tumor growth inhibitor. WM-A1-3389 specifically binds to the C-terminus of IGSF1, increases secretion of Granzyme B, IFN?γ, and TNF?α, and inhibits growth of colon cancer or biliary tract cancer in xenogeneic or allogeneic mouse implantation models. WM-A1-3389 can be used for the research of colon cancer, biliary tract cancer, and head and neck cancer.

Species: Human

Transmembrane Glycoprotein  
Colorectal Cancer  
/
HY-D2309 IRDye700Dx (Maleimide)
IRDye700Dx Maleimide is a Photosensitizer. When conjugated with HER2 Affibody and activated by near-infrared light, IRDye700Dx Maleimide induces death in HER2-positive breast cancer cells without causing damage to HER2-negative breast cancer cells.
Fluorescent Dye   Photosensitizer  
HER-2 Positive Breast Cancer  
/
HY-N10491 Spongionellol A
Spongionellol A is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A can be used in the research of cancers, such as prostate cancer.
P-glycoprotein  
/
HY-15150G Bemcentinib (GMP)
Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer.
TAM Receptor  
/
HY-D3185 AlDeSense AM
AlDeSense AM is a cell-permeable ALDH1A1-selective fluorescent reporter. AlDeSense AM is oxidized by ALDH1A1, which eliminates photoinduced electron transfer quenching and enhances the fluorescent signal. AlDeSense AM can be used to detect cells with cancer stem cell properties, as well as to monitor the plasticity of cancer stem cells in cell culture systems and animal models. AlDeSense AM is applicable to the study of cancers associated with cancer stem cells, including chronic myeloid leukemia, melanoma, and breast cancer.
Fluorescent Dye   Aldehyde Dehydrogenase (ALDH)  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Melanoma  
/
HY-14249S1 (R)-Bicalutamide-d5
(R)-Bicalutamide-d5 is deuterated labeled (R)-Bicalutamide (HY-108250). (R)-Bicalutamide is an androgen receptor (AR) antagonist, with antineoplastic activity. (R)-Bicalutamide is widely used for the research of prostate cancer.
Androgen Receptor   Autophagy   Isotope-Labeled Compounds  
Cancer  
/
HY-N18735 Quassia extract
Quassia extract is obtained from the Picrasma quassioides (D. Don) Benn. It has the effects of clearing away heat, removing dampness, and detoxification.
Others  
Inflammation or Immune System Disease  
/
HY-N17753 Protoneodioscin
Protoneodioscin is a furostanol saponin found in the rhizomes of Dioscorea collettii var. hypoglauca. It exhibits selective activity against various cancer cell lines, including leukemia, but shows no activity against colon and renal cancer cells. Protoneodioscin can be used in research on cancers such as leukemia.
Others  
Leukemia/Lymphoma/Myeloma  
/
HY-P992374 huDMB5F3
huDMB5F3 (DMB5F3; chDMB5F3) is a human monoclonal antibody against human CD227/MUC1, with a Ka value of 5.89 pM for its human target. huDMB5F3 enters MUC1-positive cancer cells via a temperature-dependent internalization process. huDMB5F3 induces cytotoxicity in MUC1-positive cancer cells. huDMB5F3 can be used in the research of various cancers including breast cancer, pancreatic cancer and gastric cancer.

Species: Human

Mucin  
Breast Cancer   Gastric Cancer   Pancreatic Cancer  
/
HY-180885S KRAS G12D-IN-35
KRAS G12D-IN-35 (example 7) is a potent and orally active KRAS G12D inhibitor. KRAS G12D-IN-35 suppresses p-ERK in AGS cells and potently inhibits the proliferation of various KRAS G12D-mutant cancer cell lines. KRAS G12D-IN-35 inhibits tumor growth in HPAC and GP2D mouse models. KRAS G12D-IN-35 can be used for cancer research, such as pancreatic and colorectal cancer.
Ras   ERK  
Colorectal Cancer   Pancreatic Cancer  
/
HY-P4144 Onvitrelin ucalontide
Onvitrelin ucalontide (Phor18-LHRH (338613); EP-100) is a luteinizing hormone-releasing hormone (LHRH) receptor ligand. Onvitrelin ucalontide binds to functional LHRH receptors on cancer cells and mediates targeted cytotoxicity. Onvitrelin ucalontide reduces tumor volume, weight and the number of viable tumor cells in xenograft models. Onvitrelin ucalontide can be used for the research of breast cancer, ovarian cancer and prostate cancer.
GnRH Receptor  
Breast Cancer   Prostate Cancer   Ovarian Cancer  
/
HY-170905S MAT2A-IN-22
MAT2A-IN-22 (Compound 29-1) is a BBB-penetrable and orally active MAT2A inhibitor with an IC50 of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects.
Methionine Adenosyltransferase (MAT)   Isotope-Labeled Compounds  
Cancer  
/
HY-N21668 6-O-(E)-p-Hydroxy-cinnamoyl-glucose
Free Radical Scavengers  
/
HY-P10790 Breast cancer targeting peptide 18–4
Breast cancer targeting peptide 18–4 is a KRT1 receptor-targeting peptide, with a Kd of 0.98 μM. The amino acid sequence of Breast cancer targeting peptide 18–4 is WxEAAYQrFL, and it is an analogue of P160 peptide (HY-P10789). When covalently conjugated with the anticancer peptide MccJ25, Breast cancer targeting peptide 18–4 significantly increases the cellular uptake of MccJ25 in breast cancer cells and enhances its anticancer activity. The covalent conjugate exhibits IC50 values of 14.2, 20, and 25 μM against MCF-7, MDA-MB-435, and MDA-MB-435-MDR cells, respectively.
Microtubule/Tubulin  
/
HY-P1813 PSA1 (141-150)
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments.
Prostaglandin Receptor  
/
HY-N18126 13b,14-Dihydrorutaecarpine
13b,14-Dihydrorutaecarpine is a cytotoxin derived from dihydrorutaecarpine. 13b,14-Dihydrorutaecarpine exerts selective cytotoxicity against central nervous system (CNS) and prostate cancer cell lines (GI50=0.02 μM and 0.2 μM). 13b,14-Dihydrorutaecarpine can be used in the research of central nervous system (CNS) cancer, ovarian cancer, prostate cancer and renal cancer.
Others  
Prostate Cancer   Ovarian Cancer   Renal Cancer  
/
HY-164107A Auristatin S TFA
Auristatin S TFA is a potent Auristatin payload. Auristatin S TFA binds to the vinca-binding site on tubulin, thereby inhibiting microtubule assembly and inducing cell cycle arrest and apoptosis. Auristatin S TFA acts as a cytotoxic component of antibody-drug conjugates (ADCs) and exerts target-specific cytotoxicity against cancer cells. Auristatin S TFA can be used in the research of lymphoma, anaplastic large cell lymphoma and Hodgkin lymphoma.
ADC Payloads   Microtubule/Tubulin   Apoptosis  
Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
/
HY-P991378 MORAb-066
MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research.

Species: Human

Transmembrane Glycoprotein  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-P992441 PHST001
PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer.

Species: Human

Transmembrane Glycoprotein  
Ovarian Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer  
/
HY-P992473 TAS266
TAS266 is a tetrameric nanobody agonist targeting DR5. TAS266 selectively induces cancer cell death. TAS266 triggers sustained tumor regression in xenograft models and also elicits immunogenic responses including antibody binding. TAS266 exhibits superior anti-tumor efficacy compared with traditional DR5-targeting strategies. TAS266 can be used in research related to pancreatic cancer and advanced solid tumors.

Species: Human

TNF Receptor  
Inflammation or Immune System Disease   Pancreatic Cancer  
/
HY-P991634 IBI-325
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.

Species: Human

CD73   TNF Receptor   Interleukin Related   IFNAR  
Cancer   Inflammation or Immune System Disease  
/
HY-N18186 Neojiangyouaconitine
Neojiangyouaconitine is a diterpenoid alkaloid cytotoxin isolated from Aconitum soongaricum var. pubescens. Neojiangyouaconitine exhibits cytotoxic activity against human breast cancer, prostate cancer and lung cancer cells, with weak inhibitory effect on HeLa cells. Neojiangyouaconitine has the ability to kill specific tumor cell lines and can be applied to the research on the mechanisms of related cancers such as breast cancer, prostate cancer and lung cancer.
Others  
Lung Cancer   Breast Cancer   Prostate Cancer  
/
HY-20457G TL8-506 (GMP)
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy.
Toll-like Receptor (TLR)   Bacterial   Interleukin Related  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P10371 PKHB1
PKHB1 (txCD47) is a CD47 agonist and Thrombospondin-1 peptide mimetic. PKHB1 activates CD47 and triggers Caspase-independent, calcium-dependent cell death via mitochondrial alterations, ROS production, endoplasmic reticulum morphological changes, and dissipation of mitochondrial membrane potential. PKHB1 induces the exposure of Calreticulin, HSP70, and HSP90, thereby driving immunogenic cell death. PKHB1 promotes intratumoral CD8+ T cell infiltration and inhibits breast tumorigenesis. PKHB1 reduces HSV-1 levels and alleviates the severity of herpes simplex keratitis. PKHB1 can be used in research related to breast cancer, herpes simplex keratitis, and T-cell acute lymphoblastic leukemia.
Reactive Oxygen Species (ROS)   Thrombopoietin Receptor   Mitochondrial Metabolism   HSP   HSV   CD47  
Inflammation or Immune System Disease   Breast Cancer   Acute Lymphoblastic Leukemia   HSV Infection  
/
HY-P991417 LYN00101
LYN00101 is a human monoclonal antibody (mAb) targeting VEGFA. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research.

Species: Human

VEGFR  
Cancer  
/
HY-N16523 Ferruginoside C
Ferruginoside C is a phenylethanoid. Ferruginoside C can be isolated from V. leiocarpum. Ferruginoside C shows potent alpha-glucosidase inhibitory activity with an IC50 of 19.93 μM. Ferruginoside C shows antioxidant activities. Ferruginoside C can be used in the research of cervical cancer, ovarian cancer, and colon cancer.
Glycosidase  
Colorectal Cancer   Cervical Cancer   Ovarian Cancer  
/
HY-163591 PRMT5-IN-36-d3
PRMT5-IN-36-d3 is the deuterated derivative of PRMT5-IN-36. PRMT5-IN-36-d3 (compound 4) is an orally active PRMT5 inhibitor for cancer research.
Histone Methyltransferase  
Cancer  
/
HY-E70188 N-Acetylgalactosamine-6-Sulfatase
N-Acetylgalactosamine-6-Sulfatase (GALNS) is a potential general biomarker for multiple malignancies (such as lung cancer, breast cancer, head and neck cancer, etc.). N-Acetylgalactosamine-6-Sulfatase deficiency causes mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. N-Acetylgalactosamine-6-Sulfatase can be used in MPS IVA as well as cancer research.
Biochemical Assay Reagents  
/
HY-P991654 SAR228810
SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research.

Species: Human

Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-158775 Ferroptocide
Ferroptocide is a cell death inducer that triggers ferroptosis and has anti-tumor activity. Ferroptocide can induce oxidative stress, leading to G2/M cell cycle arrest and apoptosis activation in LNCaP cells, while also effectively inhibiting the cell viability of both LNCaP and TRAMP-C1 cells. Ferroptocide can be used to study its capability to induce mitochondrial autophagy and to trigger immunogenic cell death (ICD) in prostate cancer cells.
Ferroptosis   Apoptosis   Autophagy  
/
HY-N1420AS2 Rhamnose-13C-2 monohydrate
Rhamnose-13C-2 (monohydrate) is the 13C labeled Rhamnose monohydrate. Rhamnose monohydrate (L-Rhamnose monohydrate) is a monosaccharide found in plants and bacteria. Rhamnose monohydrate-conjugated immunogens is used in immunotherapies. Rhamnose monohydrate
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer  
/
HY-P991583 GP369
GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer.

Species: Human

FGFR   ERK  
Cancer  
/
HY-N2499R Dehydrotumulosic acid (Standard)
Dehydrotumulosic acid (Standard) is the analytical standard of Dehydrotumulosic acid. This product is intended for research and analytical applications. Dehydrotumulosic acid is one of the effective constituents of Poria cocos. Poria cocos, a popular Chinese medicinal herb of fungal origin, has been included in many combinations with other CM herbs for its traditionally claimed activities of inducing diuresis, excreting dampness, invigorating the spleen and tranquilizing the mind and its modern pharmacological use of modulating the immune system of the body.
Reference Standards   Others  
Metabolic or Endocrine Disease  
/
HY-122955 Xanthobaccin A
Xanthobaccin A is a potent antibiotic that can be isolated from the culture fluid of Stenotrophomonas sp. strain SB-K88. Xanthobaccin A exhibits activity against fungi and G+ bacteria, induces zoospore immobilization and lysis, inhibits mycelial growth. Xanthobaccin A can be used for the research of beet damping-off disease, bacterial and fungal infection.

Source: Stenotrophomonas sp. Strain SB-K88

Antibiotic   Fungal   Bacterial  
Bacterial Infection   Fungal Infection  
/
HY-W248121 Pyrromethene 567
Pyrromethene 567 is a commercially available BODIPY dye with a photodynamic cytotoxicity IC50 of 6.8 ± 1.8 μM.Pyrromethene 567 shows cytoplasmic localization and limited cellular uptake in cancer cells.Pyrromethene 567 can be used for the research of lung cancer.
Fluorescent Dye  
Lung Cancer  
/
HY-N0819R Raddeanin A (Standard)
Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
Reference Standards   Apoptosis   PI3K   Akt   ERK   mTOR   Wnt   β-catenin   Wee1   JNK   VEGFR   CDK  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-114169S WRG-28-d5
WRG-28-d5 is the deuterium labeled WRG-28(HY-114169).WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor, with an IC50 of 230 nM. WRG-28 inhibits tumor invasion, migration and tumor-supporting effects of cancer-associated fibroblasts (CAFs). WRG-28 inhibits metastatic
Isotope-Labeled Compounds  
Cancer  
/
HY-P2076A Dusquetide TFA
Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
p62   Bacterial  
Infection  
/
HY-D1876 ZY-2
ZY-2 is a specific fluorescent probe for pyruvate kinase M2 (PKM2). ZY-2 can image in PKM2-positive cells in a time- and concentration-dependent manner. ZY-2 can be used for the detection of cancer cells.
Fluorescent Dye  
/
HY-149631 HFY-4A
HFY-4A is a HDAC inhibitor. HFY-4A inhibits breast cancer cell proliferation, migration, and invasion, and induces cell apoptosis. HFY-4A induces immunogenic cell death (ICD). HFY-4A inhibits tumor growth in breast cancer xenograft mouse models.
HDAC  
Breast Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer  
/
HY-W1123936B DBCO-PEG1000-FA
DBCO-PEG1000-FA (DBCO-PEG1000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications.
Folate Receptor (FR)  
Cancer  
/
HY-177414 BB-1701
BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 consists of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), and a microtubule inhibitor (Eribulin) (HY-13442), with the drug-linker conjugate of the ADC being Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 exhibits potent cytotoxicity against various cancer cells, shows a remarkable bystander effect, and induces immunogenic cell death (upregulated cell surface expression of calreticulin, release of ATP/HMGB1, macrophage infiltration) and apoptosis. BB-1701 potently inhibits tumor growth in T-DM1/T-DXd-resistant tumor models. BB-1701 can be used in studies related to breast cancer, gastric cancer, non-small cell lung cancer, and heterogeneous mixed tumors.
Antibody-Drug Conjugates (ADCs)   EGFR   Apoptosis  
Inflammation or Immune System Disease   Breast Cancer   Gastric Cancer   Non-Small Cell Lung Cancer  
/
HY-P991126 Ciltistotug
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-W001974 7-Nitroindole
7-Nitroindole is a cleavable base analog and Antibacterial agent. 7-Nitroindole inhibits the growth of Lactobacillus arabinosus. 7-Nitroindole is used in studies of light-controlled DNA cleavage and Lactobacillus arabinosus infection.
DNA/RNA Synthesis   Bacterial  
/
HY-N1420AS Rhamnose-13C monohydrate
Rhamnose-13C (monohydrate) is the 13C labeled Rhamnose monohydrate. Rhamnose monohydrate (L-Rhamnose monohydrate) is a monosaccharide found in plants and bacteria. Rhamnose monohydrate-conjugated immunogens is used in immunotherapies. Rhamnose monohydrate c
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer  
/
HY-159061 Antrodia Camphorata Extract
Antrodia Camphorata Extract can be isolated from Antrodia camphorata. Antrodia camphorata is a well-known traditional Chinese medicine that has been shown to inhibit proliferation and migration of cancer cells.
Biochemical Assay Reagents  
/
HY-W259888 (R)-2-Hydroxysuccinic acid methyl ester
(R)-2-Hydroxysuccinic acid methyl ester is a biochemical that can be used for the research of cancer or amyloidosis.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-P10217 PD-1/PD-L1-IN-42
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-N0789 Delsoline
Delsoline, a major alkaloid of Delphinium anthriscifolium Hance, has both a curare-like effect and a ganglion-blocking effect and is used to relieve muscle tension or hyperkinesia. D. anthriscifolium Hance has effects of dispelling wind and dampness, activating collaterals, and relieving pains and is used to treat rheumatism, hemiplegia, indigestion, and cough.
Others  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P11347 NOTA-AUNP-12
NOTA-AUNP-12 is a PD-L1 antagonist (IC50=2.24×10−7 M). NOTA-AUNP-12 is promising for research of cancers (e.g., lung/esophageal cancers).
PD-1/PD-L1  
Cancer  
/
HY-P99551 Tosatoxumab
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992).

Species: Human

Antibiotic   Bacterial  
Staphylococcus Aureus Infection  
/
HY-P991681 Emaretamig
Emaretamig is a humanized IgG1κ monoclonal antibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research.

Species: Human

Claudin   CD3  
Cancer  
/
HY-P991176 RG-6333
RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001).

Species: Human

CD19   CD28  
Cancer  
/
HY-145622 Mecbotamab vedotin
Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162).
Antibody-Drug Conjugates (ADCs)   TAM Receptor  
Cancer  
/
HY-176785S MCB-294
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
Ras   Apoptosis   p38 MAPK   Caspase   TNF Receptor  
/
HY-P10862A AH-D peptide TFA
AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.
Exosomes   Virus Protease  
Cancer   Infection  
/
HY-P11205A Cys-PKHB1 TFA
Cys-PKHB1 (Cys-txCD47) TFA is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
CD47   Reactive Oxygen Species (ROS)   Thrombopoietin Receptor  
Inflammation or Immune System Disease  
/
HY-P3486 GADGVGKSAL
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P10862 AH-D peptide
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with
IC50
values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1+ exosomes, reducing intratumoral immunosuppressive cells (regulatory T cells, myeloid-derived suppressor cells), and enhancing T cell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis.
Exosomes   Virus Protease  
Cancer   Infection  
/
HY-P3487 GAGGVGKSA
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-Y1097S Monomethyl phthalate-d4
Monomethyl phthalate-d4 (2-(Methoxycarbonyl)benzoic acid-d4) is the deuterium labeled Monomethyl phthalate. Monomethyl phthalate is a phthalate metabolite. Monomethyl phthalate acts as a urinary biomarker of phthalates exposure and can be used as a standard for the determination of thyroid cancer and benign nodule.
Isotope-Labeled Compounds  
Cancer  
/
HY-P99834 Crefmirlimab
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.

Species: Human

Transmembrane Glycoprotein  
Lung Cancer  
/
HY-201263 p-SCN-Bn-TCMC
p-SCN-Bn-TCMC is a bifunctional chelator. Its cyclen backbone binds Hg2+, while its isothiocyanate group allows for conjugation to biomolecules. p-SCN-Bn-TCMC can be used in the research of prostate cancer.
Biochemical Assay Reagents  
Cancer  
/
HY-N1420AR Rhamnose monohydrate (Standard)
Rhamnose monohydrate (Standard) is the analytical standard of Rhamnose monohydrate (HY-N1420A). Rhamnose monohydrate (L-Rhamnose monohydrate) is an orally active deoxysugar. Rhamnose monohydrate can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose monohydrate can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose monohydrate shows anti-aging effects. Rhamnose monohydrate can be used in the study of Ehrlich’s solid tumors and sarcomas.
Reference Standards   Endogenous Metabolite   MMP   Interleukin Related   PKA  
Cancer   Infection   Metabolic or Endocrine Disease  
/
HY-P11107 RP-832c
RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (Kd = 3.5 μM). RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF).
Apoptosis   TNF Receptor  
Inflammation or Immune System Disease  
/
HY-P1828A EGFRvIII peptide (PEPvIII) TFA
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy.
EGFR  
Cancer  
/
HY-P3488 GADGVGKSA
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-W115609 N-Phenylbenzamide
N-Phenylbenzamide (N-Benzoylaniline) is a compound skeleton. N-Phenylbenzamide can be used for the researches of cancer and infection, such as enterovirus and cervical cancer.
Enterovirus   Biochemical Assay Reagents  
Infection  
/
HY-121462 Cyanine
Cyanine is an excellent fluorescent core scaffold for constructing fluorescent probes. Covalent conjugation of Cyanine with other potent compounds can not only enhance their efficacy but also expand their application modes. Cyanine supports the development of cancer theranostic agents. Cyanine can be used in cancer research.
Fluorescent Dye  
Cancer  
/
HY-P11058 OVA(250-264)
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
MHC  
/
HY-P99181 Mupadolimab
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells.

Species: Human

CD73  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   SARS-CoV-2 Infection  
/
HY-P990717 Brenetafusp
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3+ T cells to kill PRAME+ tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer.

Species: Human

CD3  
Cancer  
/
HY-78216 2-Thiooxamic acid ethyl ester
2-Thiooxamic acid ethyl ester is an organic compound containing thiocarbonyl and ethyl ester groups. 2-Thiooxamic acid ethyl ester can be used in the study of cancer (such as chronic myeloid leukemia, breast cancer, etc.) .
Biochemical Assay Reagents  
Cancer  
/
HY-N2499 Dehydrotumulosic acid
Dehydrotumulosic acid is one of the effective constituents of Poria cocos. Poria cocos, a popular Chinese medicinal herb of fungal origin, has been included in many combinations with other CM herbs for its traditionally claimed activities of inducing diuresis, excreting dampness, invigorating the spleen and tranquilizing the mind and its modern pharmacological use of modulating the immune system of the body.
Others  
Metabolic or Endocrine Disease  
/
HY-P2076 Dusquetide
Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
p62   Bacterial  
Infection  
/
HY-W782083 p-SCN-Bn-NOTA trihydrochloride
p-SCN-Bn-NOTA trihydrochloride is a macrocyclic chelator. p-SCN-Bn-NOTA trihydrochloride can be covalently coupled to molecules such as peptides through the thiocyanate group to form hexacoordinate copper (such as 64Cu) complexes. p-SCN-Bn-NOTA trihydrochloride specifically binds to GRPR or EGFR highly expressed on the surface of tumor cells, mediating tumor enrichment of radioactive probes. p-SCN-Bn-NOTA trihydrochloride can be used to study malignant tumors expressing GRPR or EGFR, such as prostate cancer and colorectal cancer.
Biochemical Assay Reagents   Radionuclide-Drug Conjugates (RDCs)   Bombesin Receptor   EGFR  
/
HY-P1654 A20FMDV2
A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC50 values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma.
Integrin  
Breast Cancer   Colorectal Cancer   Pancreatic Cancer   Ovarian Cancer  
/
HY-P99683 Ladiratuzumab vedotin
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer.
Antibody-Drug Conjugates (ADCs)  
Metastatic Breast Cancer  
/
HY-13442AS Eribulin-d3 mesylate
Eribulin-d3 (mesylate) is a deuterium labeled Eribulin mesylate. Eribulin mesylate is a microtubule targeting agent that is used for the research of cancer.
Microtubule/Tubulin   Apoptosis  
Cancer  
/
HY-P99189 Cixutumumab
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.

Species: Human

IGF-1R  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Large Cell Lung Carcinoma   HER-2 Positive Breast Cancer   Metastatic Breast Cancer  
/
HY-P99175 KWAR 23
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

Species: Human

CD47  
Cancer  
/
HY-156002 LUNA18
LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer.
Ras   ERK  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-131498 Mca-PLGL-Dpa-AR-NH2
MOCAc-PLGL (Dpa) AR (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) is a synthetic fluorescent substrate mainly used for in vitro enzymatic activity assays of MMP-7 (detection at 393 nm after excitation at 328 nm). MOCAc-PLGL (Dpa) AR is specifically cleaved and hydrolyzed by MMP-7 at the Gly-Leu peptide bond, allowing enzymatic activity to be monitored via fluorometry or HPLC (DMSO is usually added to ensure sufficient dissolution when determining kinetic parameters). MOCAc-PLGL (Dpa) AR is used to accurately evaluate the catalytic activity and pH dependence of recombinant mature human MMP-7 in vitro. MOCAc-PLGL (Dpa) AR is suitable for research on the mechanisms of tumor metastasis and invasion, particularly in fields such as prostate cancer, colon cancer, lung cancer and breast cancer.\n
Fluorescent Dye   MMP  
Cancer   Digestive System Cancer   Urogenital Cancer  
/
HY-145974A m7GpppAmpG ammonium solution (100 mM)
m7GpppAmpG ammonium (m7G(5')ppp(5')(2'OMeA)pG ammonium) is a trinucleotide 5′ end cap analog. m7GpppAmpG ammonium binds to eIF4E with a KD value of 45.6 nM. m7GpppAmpG ammonium caps RNA with a capping efficiency of 90%. m7GpppAmpG ammonium enhances mRNA stability and translation efficiency. m7GpppAmpG ammonium is used in mRNA therapeutic research.
DNA/RNA Synthesis   Eukaryotic Initiation Factor (eIF)  
/
HY-P9933 Dinutuximab
Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer.
Apoptosis   PERK   mTOR  
Breast Cancer  
/
HY-159127 HRS-4642
HRS-4642 is a high affinity, selective, long-acting, and non-covalent KRASG12D inhibitor with a Kd value of 0.083 nM. HRS-4642 inhibits the binding of KRASG12D to SOS1 or RAF1, thereby blocking the downstream MEK-ERK signaling pathway. HRS-4642 promotes Apoptosis. HRS-4642 alone or combined with Carfilzomib (HY-10455) effectively shapes the tumor microenvironment. HRS-4642 has an anti-cancer effect on pancreatic and colorectal cancers carrying the KRASG12D mutation.
Ras   MEK   PERK   Apoptosis  
Colorectal Cancer   Pancreatic Cancer  
/
HY-P10587 Icotrokinra
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.
Interleukin Related   STAT   IFNAR  
Inflammation or Immune System Disease  
/
HY-P71043 SNCG Protein, Human
SNCG proteins help maintain the integrity of neurofilament networks and may influence axonal structure during development and adulthood. In vitro, it enhances the sensitivity of neurofilament-H to calcium-dependent proteases. SNCG Protein, Human is the recombinant human-derived SNCG protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

/
HY-P71928 TFF1 Protein, Human
TFF1 protein functions as a mucous gel stabilizer, vital for fortifying the gastrointestinal mucosa against noxious agents. It contributes to the mucous layer's integrity, providing a crucial physical barrier for the gastrointestinal tract, safeguarding it from potential harm. TFF1's stabilizing role emphasizes its significance in preserving the mucosal barrier, essential for overall gastrointestinal health and protection. TFF1 Protein, Human is the recombinant human-derived TFF1 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Cytokines and Growth Factors

/
HY-P703091 BRCA1 Protein, Human
BRCA1 Protein, Human is the recombinant human-derived BRCA1, expressed by E. coli, with tag free labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P7677 BIN2 Protein, Human (His)
BIN2 Protein, Human (His) is a recombinant human bridging integrator 2 (BIN2) with a His tag.

Species: Human; Source: E. coli

/
HY-P705526 GADD34/PPP1R15A Protein, Human (His)

Species: Human; Source: E. coli

/
HY-P72054 RCVRN Protein, Human (sf9, His-Myc)
The RCVRN protein is a calcium sensor that regulates phototransduction in cone and rod photoreceptors, enhancing the light sensitivity of cone photoreceptors in dark conditions. Under low light, it prolongs RHO/rhodopsin activation in rod photoreceptor cells by inhibiting GRK1-mediated phosphorylation. RCVRN Protein, Human (sf9, His-Myc) is the recombinant human-derived RCVRN protein, expressed by sf9 insect cells , with N-10*His, C-Myc labeled tag.

Species: Human; Source: Sf9 insect cells

/
HY-P71778 RCVRN Protein, Human (P.pastoris, His)
The RCVRN protein is a calcium sensor that regulates phototransduction in cone and rod photoreceptors, enhancing the light sensitivity of cone photoreceptors in dark conditions. Under low light, it prolongs RHO/rhodopsin activation in rod photoreceptor cells by inhibiting GRK1-mediated phosphorylation. RCVRN Protein, Human (P.pastoris, His) is the recombinant human-derived RCVRN protein, expressed by P. pastoris , with N-His labeled tag.

Species: Human; Source: P. pastoris

/
HY-P76849 CSAG1 Protein, Human (HEK293, Fc)
CSAG1 Protein is a potential key player in maintaining centrosome integrity during mitosis, impacting chromosome segregation. The mechanisms underlying its contribution to centrosome stability require elucidation. Its putative involvement highlights significance in mitosis-related cellular events. Further research is essential to unravel precise details of CSAG1's function and its implications for centrosome integrity during mitosis. CSAG1 Protein, Human (HEK293, Fc) is the recombinant human-derived CSAG1 protein, expressed by HEK293 , with N-hFc labeled tag.

Species: Human; Source: HEK293

/
HY-P73700 PRAC Protein, Human (His-SUMO)
PRAC Protein exhibits high expression in the prostate, rectum, and distal colon, with weaker expression in the bladder. Its prominence in prostate cancer cell lines suggests a potential link to prostate cancer pathology. The tissue-specific expression emphasizes PRAC Protein's potential roles in normal physiological processes and cancer contexts. PRAC Protein, Human (His-SUMO) is the recombinant human-derived PRAC protein, expressed by E. coli , with N-His, N-SUMO labeled tag.

Species: Human; Source: E. coli

/
HY-P703092 BRCA2 Protein, Human (HEK293, His, Strep, Flag)
BRCA2 Protein, Human (HEK293, His, Strep, Flag) is the recombinant human-derived BRCA2, expressed by HEK293, with Strep, His, Flag labeled tag.

Species: Human; Source: HEK293

/
HY-P86790 BRCA2 Antibody (YA6483)
BRCA2 Antibody (YA6483) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRCA2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86827 CTAG1B Antibody (YA6520)
CTAG1B Antibody (YA6520) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CTAG1B.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P811127 Recoverin Antibody
Recoverin Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Recoverin.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P811296 CTAG1B Antibody
CTAG1B Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to CTAG1B.

Host: Rabbit; Reactivity: Human

Polyclonal Antibodies Primary Antibodies

/
HY-P83052 CEP55 Antibody (YA2797)
CEP55 Antibody (YA2797) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CEP55.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83052A CEP55 Antibody (YA2797)(PBS only)
CEP55 Antibody (YA2797) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CEP55.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86253 NABC1 Antibody (YA5945)
NABC1 Antibody (YA5945) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NABC1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86753 MUC16 Antibody (YA6445)
MUC16 Antibody (YA6445) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86753A MUC16 Antibody (YA6445)(PBS only)
MUC16 Antibody (YA6445) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P87366 BLCAP Antibody (YA7049)
BLCAP Antibody (YA7049) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to BLCAP.

Host: Mouse; Reactivity: Human, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-K2033 OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology to achieve highly efficient nucleic acid(eg. pDNA、mRNA、sgRNA、siRNA) delivery into Jurkat cells. It is designed for in vitro transfection of Jurkat cells and is well suited for applications in immunotherapy, tumor immunology, and other immune cell-related research.

Cell Biology Cell Culture Cell Transfection

/
HY-K6101 Human Breast Cancer Organoid Kit

MCE Human Breast Cancer Organoid Kit contains Breast Cancer Organoid Basal Medium A, Breast Cancer Organoid Supplement B (50×), Breast Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human breast cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6103 Human Small Cell Lung Cancer Organoid Kit

MCE Human Small Cell Lung Cancer Organoid Kit contains Small Cell Lung Cancer Organoid Basal Medium A, Small Cell Lung Cancer Organoid Supplement B (50×),Small Cell Lung Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human small cell lung cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6104 Human Colorectal Cancer Organoid Kit

MCE Human Colorectal Cancer Organoid Kit contains Colorectal Cancer Organoid Basal Medium A, Colorectal Cancer Organoid Supplement B (50×), Colorectal Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human colorectal cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6107 Human Cervical Cancer Organoid Kit

MCE Human Cervical cancer Organoid Kit contains Cervical cancer Organoid Basal Medium A, Cervical cancer Organoid Supplement B (50×), Cervical cancer Organoid Supplement C (250×). This product can be used to efficiently construct human cervical cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6108 Human Esophageal Cancer Organoid Kit

MCE Human Esophageal Cancer Organoid Kit contains Esophageal Cancer Organoid Basal Medium A, Esophageal Cancer Organoid Supplement B (50×), Esophageal Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human esophageal cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6109 Human Endometrial Cancer Organoid Kit

MCE Human Endometrial Cancer Organoid Kit contains Endometrial Cancer Organoid Basal Medium A, Endometrial Cancer Organoid Supplement B (50×), Endometrial Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human endometrial cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6110 Human Pancreatic Cancer Organoid Kit

MCE Human Pancreatic Cancer Organoid Kit contains Pancreatic Cancer Organoid Basal Medium A, Pancreatic Cancer Organoid Supplement B (50×), Pancreatic Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human pancreatic cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6123 Human Ovarian Cancer Organoid Kit

MCE Human Ovarian Cancer Organoid Kit includes a basic culture medium for ovarian cancer organoids, as well as culture supplements, and is designed for the effective construction of human ovarian cancer organoids.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6126 Human Kidney Cancer Organoid Kit

MCE Human Kidney Cancer Organoid Kit includes a basic culture medium for Kidney Cancer organoids, as well as culture supplements, and is designed for the effective construction of human Kidney Cancer organoids.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/

References

[1]. Babu, T., Levine, M. S., Acharya, S., Maier, E. Y., & Sessler, J. L. (2025). Three Is Better than One: A Multimetal Complex that Triggers Immunogenic Cell Death. Angewandte Chemie (International ed. in English), 64(39), e202514351.  [Content Brief]

[2]. Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017). Immunogenic cell death in cancer and infectious disease. Nature reviews. Immunology, 17(2), 97–111.  [Content Brief]

[3]. Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017). Immunogenic cell death in cancer and infectious disease. Nature reviews. Immunology, 17(2), 97–111.  [Content Brief]

[4]. Ahmed, A., & Tait, S. W. G. (2020). Targeting immunogenic cell death in cancer. Molecular oncology, 14(12), 2994–3006. https://doi.org/10.1002/1878-0261.12851  [Content Brief]

[5]. Meier, P., Legrand, A. J., Adam, D., & Silke, J. (2024). Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nature reviews. Cancer, 24(5), 299–315.  [Content Brief]

[6]. Zhang, Z., Pan, Z., Li, Q., Huang, Q., Shi, L., & Liu, Y. (2024). Rational design of ICD-inducing nanoparticles for cancer immunotherapy. Science advances, 10(6), eadk0716.  [Content Brief]

[7]. Li, Z., Lai, X., Fu, S., Ren, L., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K. (2022). Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 9(22), e2201734.  [Content Brief]

[8]. Galluzzi, L., Kepp, O., Hett, E., Kroemer, G., & Marincola, F. M. (2023). Immunogenic cell death in cancer: concept and therapeutic implications. Journal of translational medicine, 21(1), 162.  [Content Brief]

Keywords

Cancer | Immunogenic Cell Death | Immunotherapy | DAMPs